BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kraft S, Bollinger N, Bodenmann B, Heim D, Bucher C, Lengerke C, Kleber M, Tsakiris DA, Passweg J, Tzankov A, Medinger M. High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease. Bone Marrow Transplant 2019;54:540-8. [DOI: 10.1038/s41409-018-0293-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Sagou K, Fukushima N, Ukai S, Goto M, Ozeki K, Kohno A. Clinical usefulness of diagnostic criteria for transplant-associated thrombotic microangiopathy. Int J Hematol 2020;112:697-706. [DOI: 10.1007/s12185-020-02963-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Furukawa M, Wang X, Ohkawara H, Fukatsu M, Alkebsi L, Takahashi H, Harada-Shirado K, Shichishima-Nakamura A, Kimura S, Ogawa K, Ikezoe T. A critical role of the Gas6-Mer axis in endothelial dysfunction contributing to TA-TMA associated with GVHD. Blood Adv 2019;3:2128-43. [PMID: 31300420 DOI: 10.1182/bloodadvances.2019000222] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
3 Bianchi M, Heim D, Lengerke C, Halter J, Gerull S, Kleber M, Tsakiris DA, Passweg J, Tzankov A, Medinger M. Cyclosporine levels > 195 μg/L on day 10 post-transplant was associated with significantly reduced acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Ann Hematol 2019;98:971-7. [DOI: 10.1007/s00277-018-3577-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
4 Gavriilaki E, Ho VT, Schwaeble W, Dudler T, Daha M, Fujita T, Jodele S. Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy. Exp Hematol Oncol 2021;10:57. [PMID: 34924021 DOI: 10.1186/s40164-021-00249-8] [Reference Citation Analysis]
5 Okamura H, Nakamae H, Shindo T, Ohtani K, Hidaka Y, Ohtsuka Y, Makuuchi Y, Kuno M, Takakuwa T, Harada N, Nishimoto M, Nakashima Y, Koh H, Hirose A, Nakamae M, Wakamiya N, Hino M, Inoue N. Early Elevation of Complement Factor Ba Is a Predictive Biomarker for Transplant-Associated Thrombotic Microangiopathy. Front Immunol 2021;12:695037. [PMID: 34326846 DOI: 10.3389/fimmu.2021.695037] [Reference Citation Analysis]
6 Henry N, Mellaza C, Fage N, Beloncle F, Genevieve F, Legendre G, Orvain C, Garnier AS, Cousin M, Besson V, Subra JF, Duveau A, Augusto JF, Brilland B. Retrospective and Systematic Analysis of Causes and Outcomes of Thrombotic Microangiopathies in Routine Clinical Practice: An 11-Year Study. Front Med (Lausanne) 2021;8:566678. [PMID: 33718396 DOI: 10.3389/fmed.2021.566678] [Reference Citation Analysis]
7 Dalla Via V, Halter JP, Gerull S, Arranto C, Tichelli A, Heim D, Passweg JR, Medinger M, Cesana-Nigro N. New-onset Post-transplant Diabetes and Therapy in Long-term Survivors After Allogeneic Hematopoietic Stem Cell Transplantation. In Vivo 2020;34:3545-9. [PMID: 33144466 DOI: 10.21873/invivo.12197] [Reference Citation Analysis]
8 Jodele S, Sabulski A. Transplant-associated thrombotic microangiopathy: elucidating prevention strategies and identifying high-risk patients. Expert Rev Hematol 2021;14:751-63. [PMID: 34301169 DOI: 10.1080/17474086.2021.1960816] [Reference Citation Analysis]
9 Dvorak CC, Higham C, Shimano KA. Transplant-Associated Thrombotic Microangiopathy in Pediatric Hematopoietic Cell Transplant Recipients: A Practical Approach to Diagnosis and Management. Front Pediatr 2019;7:133. [PMID: 31024873 DOI: 10.3389/fped.2019.00133] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
10 Imus PH, Tsai HL, DeZern AE, Jerde K, Swinnen LJ, Bolaños-Meade J, Luznik L, Fuchs EJ, Wagner-Johnston N, Huff CA, Gladstone DE, Ambinder RF, Gocke CB, Ali SA, Borrello IM, Varadhan R, Brodsky R, Jones RJ. Thrombotic Microangiopathy after Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. Biol Blood Marrow Transplant 2020;26:2306-10. [PMID: 32961372 DOI: 10.1016/j.bbmt.2020.09.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Milone G, Bellofiore C, Leotta S, Milone GA, Cupri A, Duminuco A, Garibaldi B, Palumbo G. Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology. J Clin Med 2022;11:623. [PMID: 35160072 DOI: 10.3390/jcm11030623] [Reference Citation Analysis]
12 Yang L, Zhao P, Wu Y, Fu H, He Y, Mo X, Lv M, Wang F, Yan C, Chen Y, Chang Y, Xu L, Liu K, Huang X, Zhang X. Treatment outcome and efficacy of therapeutic plasma exchange for transplant-associated thrombotic microangiopathy in a large real-world cohort study. Bone Marrow Transplant. [DOI: 10.1038/s41409-022-01581-1] [Reference Citation Analysis]
13 Karakioulaki M, Martinez M, Medinger M, Heim D, Passweg JR, Tsakiris DA. Peripheral blood schistocytes in the acute phase after allogeneic or autologous stem cell transplantation assessed by digital microscopy. Int J Lab Hem 2019;42:145-51. [DOI: 10.1111/ijlh.13130] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
14 Zhang R, Zhou M, Qi J, Miao W, Zhang Z, Wu D, Han Y. Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis. Front Immunol 2020;11:564647. [PMID: 33552043 DOI: 10.3389/fimmu.2020.564647] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Amonoo HL, Harnedy LE, Deary EC, Traeger L, Brown LA, Daskalakis EP, Cutler C, Kelkar AH, Rosales R, Goldschen L, Pirl WF, Feig EH, Revette A, Lee SJ, Huffman JC, El-Jawahri A. Peer support in patients with hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT): a qualitative study. Bone Marrow Transplant 2022. [PMID: 35589998 DOI: 10.1038/s41409-022-01711-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Van de Louw A, Cohrs A, Leslie D. Clinical Features and Outcome of Thrombotic Microangiopathies: Comparison between Patients with and without Malignancy. Thromb Haemost 2021;121:565-72. [PMID: 33186993 DOI: 10.1055/s-0040-1720974] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Ehmann MA, Medinger M, Bodenmann B, Kraft S, Bollinger N, Heim D, Lengerke C, Tsakiris DA, Passweg J, Tzankov A, Menter T. Histologic features of hematopoietic stem cell transplant-associated thrombotic microangiopathy are best percepted in deep skin biopsies and renal biopsies, while showing a significant overlap with changes related to severe acute graft-versus-host disease in gastrointestinal biopsies. Bone Marrow Transplant 2020;55:1847-50. [PMID: 32231248 DOI: 10.1038/s41409-020-0880-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
18 Zhang Z, Wang H, Qi J, Tang Y, Cai C, Zhou M, Pan T, Wu D, Han Y. Acute graft-versus-host disease increase risk and accuracy in prediction model of transplantation-associated thrombotic microangiopathy in patients with myelodysplastic syndrome. Ann Hematol 2022. [PMID: 35357522 DOI: 10.1007/s00277-022-04820-z] [Reference Citation Analysis]
19 Mezö B, Horváth O, Sinkovits G, Veszeli N, Kriván G, Prohászka Z. Validation of Early Increase in Complement Activation Marker sC5b-9 as a Predictive Biomarker for the Development of Thrombotic Microangiopathy After Stem Cell Transplantation. Front Med (Lausanne) 2020;7:569291. [PMID: 33117830 DOI: 10.3389/fmed.2020.569291] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
20 Epperla N, Li A, Logan B, Fretham C, Chhabra S, Aljurf M, Chee L, Copelan E, Freytes CO, Hematti P, Lazarus HM, Litzow M, Nishihori T, Olsson RF, Prestidge T, Saber W, Wirk B, Yared JA, Loren A, Pasquini M. Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy. Br J Haematol 2020;189:1171-81. [PMID: 32124435 DOI: 10.1111/bjh.16457] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
21 Moiseev IS, Tsvetkova T, Aljurf M, Alnounou RM, Bogardt J, Chalandon Y, Drokov MY, Dvirnyk V, Faraci M, Friis LS, Giglio F, Greinix HT, Kornblit BT, Koelper C, Koenecke C, Lewandowski K, Niederwieser D, Passweg JR, Peczynski C, Penack O, Peric Z, Piekarska A, Ronchi PE, Rovo A, Rzepecki P, Scuderi F, Sigrist D, Siitonen SM, Stoelzel F, Sulek K, Tsakiris DA, Wilkowojska U, Duarte RF, Ruutu T, Basak GW. Clinical and morphological practices in the diagnosis of transplant-associated microangiopathy: a study on behalf of Transplant Complications Working Party of the EBMT. Bone Marrow Transplant 2019;54:1022-8. [DOI: 10.1038/s41409-018-0374-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
22 Heybeli C, Sridharan M, Alkhateeb HB, Villasboas Bisneto JC, Buadi FK, Chen D, Dingli D, Dispenzieri A, Gertz MA, Go RS, Hashmi SK, Hayman SR, Hogan WJ, Inwards DJ, Kenderian SS, Kumar SK, Litzow MR, Porrata LF, Lacy MQ, Micallef IN, Patnaik MM, Shah MV, Leung N. Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation. Am J Hematol 2020. [PMID: 32618000 DOI: 10.1002/ajh.25922] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
23 Adachi Y, Ozeki K, Ukai S, Sagou K, Fukushima N, Kohno A. Permanent Impairment-Free, Relapse-Free Survival: A Novel Composite Endpoint to Evaluate Long-Term Success in Allogeneic Transplantation. Biol Blood Marrow Transplant 2020;26:1005-12. [PMID: 32035276 DOI: 10.1016/j.bbmt.2020.01.025] [Reference Citation Analysis]
24 Jodele S, Medvedovic M, Luebbering N, Chen J, Dandoy CE, Laskin BL, Davies SM. Interferon-complement loop in transplant-associated thrombotic microangiopathy. Blood Adv 2020;4:1166-77. [PMID: 32208488 DOI: 10.1182/bloodadvances.2020001515] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 16.0] [Reference Citation Analysis]
25 Jodele S, Dandoy CE, Lane A, Laskin BL, Teusink-Cross A, Myers KC, Wallace G, Nelson A, Bleesing J, Chima RS, Hirsch R, Ryan TD, Benoit S, Mizuno K, Warren M, Davies SM. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Blood 2020;135:1049-57. [PMID: 31932840 DOI: 10.1182/blood.2019004218] [Cited by in Crossref: 14] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
26 Yamada R, Nemoto T, Ohashi K, Tonooka A, Horiguchi SI, Motoi T, Hishima T. Distribution of Transplantation-Associated Thrombotic Microangiopathy (TA-TMA) and Comparison between Renal TA-TMA and Intestinal TA-TMA: Autopsy Study. Biol Blood Marrow Transplant 2020;26:178-88. [PMID: 31491486 DOI: 10.1016/j.bbmt.2019.08.025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
27 Matsui H, Arai Y, Imoto H, Mitsuyoshi T, Tamura N, Kondo T, Kanda J, Ishikawa T, Imada K, Ueda Y, Toda Y, Anzai N, Yago K, Nohgawa M, Yonezawa A, Tsunemine H, Itoh M, Yamamoto K, Tsuji M, Moriguchi T, Takaori-Kondo A; Kyoto Stem Cell Transplantation Group (KSCTG). Risk factors and appropriate therapeutic strategies for thrombotic microangiopathy after allogeneic HSCT. Blood Adv 2020;4:3169-79. [PMID: 32658984 DOI: 10.1182/bloodadvances.2020002007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]